Amylyx's Treatment for Post-Bariatric Hypoglycemia Meets Primary, Secondary Endpoints in Late-Stage Trial
Dow Jones2026/08/18 11:32By Connor Hart
Amylyx Pharmaceuticals said a late-stage trial of its treatment for post-bariatric hypoglycemia met all of its primary and secondary goals.
Post-bariatric hypoglycemia is a chronic metabolic condition that can arise following weight-loss surgeries and causes recurrent and often debilitating low blood sugar.
Amylyx before Tuesday's opening bell said its treatment - avexitide, an investigational, first-in-class GLP-1 receptor antagonist - met the primary endpoint of a recent late-stage study, demonstrating a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared with placebo.
The treatment additionally met all secondary endpoints, Amylyx added.
Shares jumped 21%, to $26, in premarket trading.
The trial enrolled 78 patients with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. Avexitide was generally well-tolerated through the double-blind study period, with a consistent and favorable safety profile replicated across all trials to date, the company said.
Looking ahead, Amylyx plans to submit a new drug application to the Food and Drug Administration by the end of 2026. The FDA previously granted avexitide breakthrough-therapy designation.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 18, 2026 07:32 ET (11:32 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The “outlier” in the AI capital expenditure frenzy: Apple (AAPL.US) keeps spending flat, accounting for less than 5% of sales
Apple continues to stand out among major tech peers, largely avoiding the aggressive wave of capital expenditure associated with artificial intelligence (AI) infrastructure.
Youth Employment Declines for 48 Consecutive Months: Behind the Semiconductor Boom, Young South Koreans Are Being Left Behind by the Times
In South Korea, the unemployment rate in October fell to a three-year low of 2.5%. However, the number of employed people decreased by 50,000, youth employment has declined for 48 consecutive months, and domestic demand remains weak.
Strategy (MSTR.US) Faces Potential Removal from MSCI Index, Passive Funds May Sell $2.8 Billion
MicroStrategy is expected to be removed from the MSCI Global Investable Market Index. JPMorgan estimates that passive funds may sell about $2.8 billion worth of shares, and if removed from multiple indexes simultaneously, the scale could reach up to $8.8 billion. Additionally, with BTC falling below its average cost of $75,456, the company’s stock price and financing capacity are under dual pressure.
Crypto prices
More
